E-LIB Suche - Ergebnisse für: Izutsu, K.

1

PHASE 3 TRIAL OF SUBCUTANEOUS EPCORITAMAB + R‐CHOP VERSUS R..:

Sehn, L. H ; Chamuleau, M. ; Lenz, G....
Hematological Oncology. 41 (2023) S2 - p. 849-850 , 2023

Link: https://doi.org/10.1002/..

2

PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE ..:

Shah, NN ; Zinzani, PL ; Eyre, TA...
Hematology, Transfusion and Cell Therapy. 45 (2023) - p. S359-S360 , 2023

Link: https://doi.org/10.1016/..

3

Duvelisib in patients with relapsed/refractory peripheral T..:

Mehta‐Shah, N. ; Jacobsen, E. D. ; Zinzani, P. L....
Hematological Oncology. 41 (2023) S2 - p. 499-500 , 2023

Link: https://doi.org/10.1002/..

4

TRANSCEND FL: PHASE 2 STUDY RESULTS OF LISOCABTAGENE MARALE..:

Morschhauser, F. ; Dahiya, S. ; Palomba, M. L....
Hematological Oncology. 41 (2023) S2 - p. 877-880 , 2023

Link: https://doi.org/10.1002/..

5

IMMUNE CONTEXTURE ANALYSIS IN POLARIX SUGGESTS RESPONSE TO ..:

Morschhauser, F. ; Hatzi, K. ; Lenz, G....
Hematological Oncology. 41 (2023) S2 - p. 223-225 , 2023

Link: https://doi.org/10.1002/..

6

PIRTOBRUTINIB IN COVALENT BTK‐INHIBITOR PRE‐TREATED MANTLE ..:

Cheah, C. Y. ; Shah, N. N. ; Jurczak, W....
Hematological Oncology. 41 (2023) S2 - p. 153-156 , 2023

Link: https://doi.org/10.1002/..

7

P1192: ASIA SUBPOPULATION ANALYSIS FROM THE PHASE III POLAR..:

Song, Y. ; Jin, J. ; Tilly, H....
HemaSphere. 6 (2022) - p. 1078-1079 , 2022

Link: https://doi.org/10.1097/..

8

A PHASE 2B OPEN‐LABEL SINGLE ARM STUDY TO EVALUATE THE EFFI..:

Kim, W. S. ; Rai, S. ; Ando, K....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

9

FIRST‐IN‐HUMAN STUDY OF THE EZH1 AND EZH2 DUAL INHIBITOR VA..:

Ishitsuka, K ; Izutsu, K ; Maruyama, D...
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

10

ESCALADE: A PHASE 3 STUDY OF ACALABRUTINIB IN COMBINATION W..:

Sehn, L. H. ; Kahl, B. ; Matasar, M....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

11

OBINUTUZUMAB CAN BE ADMINISTERED AS A 90‐MINUTE SHORT‐DURAT..:

Hübel, K. ; Buchholz, T. A. ; Izutsu, K....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

12

A PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TUC..:

Izutsu, K. ; Utsunomiya, A. ; Jo, T....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

13

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PRIM..:

Kondo, E. ; Shimizu‐Koresawa, R. ; Chihara, D....
Hematological Oncology. 37 (2019) S2 - p. 266-266 , 2019

Link: https://doi.org/10.1002/..

14

CORRELATIVE ANALYSES OF CYTOKINE RELEASE SYNDROME AND NEURO..:

Bachanova, V. ; Westin, J. ; Tam, C....
Hematological Oncology. 37 (2019) S2 - p. 308-310 , 2019

Link: https://doi.org/10.1002/..

15

AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MOR..:

Gribben, J. ; Trneny, M. ; Izutsu, K....
Hematological Oncology. 37 (2019) S2 - p. 227-229 , 2019

Link: https://doi.org/10.1002/..